Status:
COMPLETED
A Long Term Study of Clozapine in Patients With Treatment-resistant Schizophrenia
Lead Sponsor:
Novartis
Conditions:
Schizophrenia
Eligibility:
All Genders
18-64 years
Phase:
PHASE2
Brief Summary
Clozapine is an antipsychotic. This open study will evaluate the safety and efficacy of long term treatment of clozapine in patients with treatment-resistant schizophrenia.
Detailed Description
Clozapine is an antipsychotic. This open study will evaluate the safety and efficacy of long term treatment of clozapine in patients with treatment-resistant schizophrenia.
Eligibility Criteria
Inclusion
- Attended the previous Phase IIb (core) study
- Improved during the core study
- No safety issues during the core study
Exclusion
- Discontinued the core study
- Pregnant or nursing (lactating) women
- Other protocol-defined exclusion criteria may apply.
Key Trial Info
Start Date :
April 1 2001
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2009
Estimated Enrollment :
19 Patients enrolled
Trial Details
Trial ID
NCT00154258
Start Date
April 1 2001
End Date
December 1 2009
Last Update
September 24 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.